NCT02923258View on ClinicalTrials.gov

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 21, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

April 30, 2023

Conditions
Oral Cavity Squamous Cell Carcinoma
Interventions
DRUG

Docetaxel

20mg/m2/w

DRUG

Cisplatin

100mg/m2/q3w

RADIATION

IMRT

a total dose of 60Gy in 30fractions over 6 weeks

Trial Locations (1)

200011

Shanghai ninth people's hospital, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

NCT02923258 - Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | Biotech Hunter | Biotech Hunter